This article was originally published in The Tan Sheet
"The opportunity to conduct placebo-controlled statin trials may soon disappear" due to trends toward broader statin use in the U.S. and UK populations, Ernest Hawk, MD, and Jaye Viner, MD, National Cancer Institute, state in a recent editorial in the New England Journal of Medicine. "Current treatment guidelines specify the use of statin therapy in patients at high risk for cardiovascular disease, but placebo-controlled testing against a variety of end points could still be ethically conducted in populations at average risk," the authors maintain. The editorial accompanies a study by Jenny Poynter, University of Michigan, et al., linking statins including Zocor (simvastatin) and Pravachol (pravastatin) to a significantly reduced relative risk of colorectal cancer...
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.